Cargando…
Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598300/ https://www.ncbi.nlm.nih.gov/pubmed/37886181 http://dx.doi.org/10.21037/hbsn-23-352 |
| _version_ | 1785125523694813184 |
|---|---|
| author | Zhang, Zunyi Zhang, Wei |
| author_facet | Zhang, Zunyi Zhang, Wei |
| author_sort | Zhang, Zunyi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10598300 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105983002023-10-26 Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy Zhang, Zunyi Zhang, Wei Hepatobiliary Surg Nutr Editorial Commentary AME Publishing Company 2023-09-04 2023-10-01 /pmc/articles/PMC10598300/ /pubmed/37886181 http://dx.doi.org/10.21037/hbsn-23-352 Text en 2023 Hepatobiliary Surgery and Nutrition. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Zhang, Zunyi Zhang, Wei Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy |
| title | Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy |
| title_full | Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy |
| title_fullStr | Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy |
| title_full_unstemmed | Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy |
| title_short | Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy |
| title_sort | conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598300/ https://www.ncbi.nlm.nih.gov/pubmed/37886181 http://dx.doi.org/10.21037/hbsn-23-352 |
| work_keys_str_mv | AT zhangzunyi conversiontherapyforadvancedcholangiocarcinomaintheeraofmoleculartargetedtherapyandimmunetherapy AT zhangwei conversiontherapyforadvancedcholangiocarcinomaintheeraofmoleculartargetedtherapyandimmunetherapy |